Arcutis Biotherapeutics Announces Health Canada Accepts for

Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety...

Related Keywords

Canada , Canadians , Canadian , Amanda Sheldon , Frank Watanabe , Exchange Commission , Twitter , Health Canada , Head Of Corporate Communications , Nasdaq , Arcutis Biotherapeutics Inc , New Drug Submission , Investigator Global Assessment ,